{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:54Z","timestamp":1790753814773,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice of antiviral treatment (AVT), given that long\u2010term safety would be a concern in the presence of multiple comorbidities. We aimed to determine the prevalence of key comorbidities and concomitant medications in a territory\u2010wide CHB cohort in Hong Kong in 2000\u20102017. CHB patients who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong. The demographics and prevalence of key comorbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia\/osteoporosis based on diagnosis codes, relevant medications, and\/or laboratory parameters, were determined according to CHB patients\u2019 first appearance in four time periods: 2000\u20102004, 2005\u20102009, 2010\u20102013, and 2014\u20102017. In the final analysis, 135,395 CHB patients were included; the mean age increased with time: 41\u00a0\u00b1\u00a015 years in 2000\u20102004; 46\u00a0\u00b1\u00a017 years in 2005\u20102009; 51\u00a0\u00b1\u00a016 years in 2010\u20102013; and 55\u00a0\u00b1\u00a015 years in 2014\u20102017. There was a trend of increasing prevalence of several common comorbidities over the four periods: hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%, respectively (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001). <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> CHB patients are getting older with increasing prevalence of common comorbidities. These comorbidities should be taken into account when choosing AVT.<\/jats:p>","DOI":"10.1002\/hep.30833","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T20:22:03Z","timestamp":1561494123000},"page":"444-455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":87,"title":["An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory\u2010Wide Study From 2000 to 2017"],"prefix":"10.1097","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai\u2010Hung","family":"Wong","sequence":"first","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"State Key Laboratory of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai\u2010Sun","family":"Wong","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"State Key Laboratory of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky Wing\u2010Yan","family":"Yuen","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee\u2010Kit","family":"Tse","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester Wing\u2010Sum","family":"Luk","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry Cheuk\u2010Fung","family":"Yip","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki Wing\u2010Ki","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Statistics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Chung\u2010Yan","family":"Lui","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik\u2010Yuen","family":"Chan","sequence":"additional","affiliation":[{"name":"Institute of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong SAR,China"},{"name":"State Key Laboratory of Digestive Disease,The Chinese University of Hong Kong,Hong Kong SAR,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"hep30833-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep30833-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/hep.30246","article-title":"Advancing age and comorbidity in a United States insured population\u2010based cohort of patients with chronic hepatitis B","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep30833-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep30833-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep30833-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17474124.2014.909724","article-title":"Current developments in nucleoside\/nucleotide analogues for hepatitis B","volume":"8","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"hep30833-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long\u2010term safety of oral anti\u2010viral treatment for chronic hepatitis B","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30833-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long\u2010term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B\u2014a cohort study of 53,500 subjects","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep30833-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30833-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30833-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/gut.2008.157735","article-title":"Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B","volume":"58","year":"2009","journal-title":"Gut"},{"key":"hep30833-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/hep.28778","article-title":"Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep30833-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2215\/CJN.06620613","article-title":"Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications","volume":"9","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"hep30833-bib-0013-20241017","first-page":"1468","article-title":"Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong","volume":"1","year":"2010","journal-title":"MEDINFO"},{"key":"hep30833-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","article-title":"Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep30833-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue\u2010treated patients","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"hep30833-bib-0016-20241017","first-page":"S13","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"hep30833-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2036.2010.04276.x","article-title":"Development of a non\u2010invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B","volume":"31","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30833-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/apt.14341","article-title":"Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis","volume":"46","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30833-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"hep30833-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment","volume":"48","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30833-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"hep30833-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg\u2010negative chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep30833-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg\u2010positive chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep30833-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30833-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"e01064\u201018","DOI":"10.1128\/AAC.01064-18","article-title":"No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"hep30833-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cgh.2014.09.050","article-title":"Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30833-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3350\/cmh.2018.0106","article-title":"Unmet need in chronic hepatitis B management","volume":"25","year":"2019","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl","key":"hep30833-bib-0028-20241017","first-page":"S25","article-title":"Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 trials in HBeAg\u2010positive and HBeAg\u2010neagtive patients with chronic hepatitis B","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30833-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non\u2010alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton\u2010magnetic resonance spectroscopy and transient elastography","volume":"61","year":"2012","journal-title":"Gut"},{"key":"hep30833-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on\u2010treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep30833-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2010Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"hep30833-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","article-title":"Hepatitis B virus infection and fatty liver in the general population","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"hep30833-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5\u2010year open\u2010label follow\u2010up study","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"hep30833-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.12658","article-title":"Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B\u2014a prospective cohort study with paired transient elastography examinations","volume":"39","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30833-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/infdis\/jiz038","article-title":"A territory\u2010wide prevalence study on blood\u2010borne and enteric viral hepatitis in Hong Kong","volume":"219","year":"2019","journal-title":"J Infect Dis"},{"key":"hep30833-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","year":"2004","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:06:42Z","timestamp":1729210002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30833","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"2019-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}